{"organizations": [], "uuid": "1a2ee79303bd94626b222c755899901aae0c4d02", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/brief-genentech-says-in-phase-3-impower1/brief-genentech-says-in-phase-3-impower150-study-survival-advantage-for-tecentriq-avastin-combo-was-seen-in-all-exploratory-patient-subgroups-analyzed-idUSFWN1SN0YY", "country": "US", "domain_rank": 408, "title": "BRIEF-Genentech Says In Phase 3 Impower150 Study, Survival Advantage For Tecentriq-Avastin Combo Was Seen In All Exploratory Patient Subgroups Analyzed", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.811, "site_type": "news", "published": "2018-05-17T05:16:00.000+03:00", "replies_count": 0, "uuid": "1a2ee79303bd94626b222c755899901aae0c4d02"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-genentech-says-in-phase-3-impower1/brief-genentech-says-in-phase-3-impower150-study-survival-advantage-for-tecentriq-avastin-combo-was-seen-in-all-exploratory-patient-subgroups-analyzed-idUSFWN1SN0YY", "ord_in_thread": 0, "title": "BRIEF-Genentech Says In Phase 3 Impower150 Study, Survival Advantage For Tecentriq-Avastin Combo Was Seen In All Exploratory Patient Subgroups Analyzed", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "genentech", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - GENENTECH:\n* PHASE III IMPOWER150 STUDY SHOWED GENENTECHâ€™S TECENTRIQ AND AVASTIN PLUS CARBOPLATIN AND PACLITAXEL HELPED PEOPLE WITH A SPECIFIC TYPE OF METASTATIC LUNG CANCER LIVE SIGNIFICANTLY LONGER COMPARED TO AVASTIN PLUS CARBOPLATIN AND PACLITAXEL\n* GENENTECH - IN PHASE III IMPOWER150 STUDY, SURVIVAL ADVANTAGE FOR TECENTRIQ-AVASTIN COMBO REGIMEN WAS SEEN IN ALL EXPLORATORY PATIENT SUBGROUPS ANALYZED Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-17T05:16:00.000+03:00", "crawled": "2018-05-17T01:45:50.011+03:00", "highlightTitle": ""}